The prevalence, presenting clinical and pathologic characteristics, and outcomes for patients with diffuse large B-cell lymphoma that is Epstein-Barr Virus positive remains uncertain as does the impact of congenital or iatrogenic immunosuppression. Patients with newly diagnosed diffuse large B-cell lymphoma with available tissue arrays were identified from the University of Iowa/Mayo Clinic Molecular Epidemiology Resource. Patients with Human Immunodeficiency Virus or prior organ transplant were excluded. Epstein-Barr-associated ribonucleic acid testing was performed on all tissue arrays. A history of significant congenital or iatrogenic immunosuppression was determined for all patients. At enrollment, 16 of the 362 (4.4%) of the biopsies were positive for Epstein-Barr Virus. 39 (10.8%) had a significant history of immunosuppression. Patients with Epstein-Barr positive diffuse large B-cell lymphoma had no unique clinical characteristics but on pathology exhibited a higher frequency of CD30 positivity (25.0% vs 8.1%; P < 0.01), and non-germinal-center subtype (62.5% vs 34.1% respectively; P < 0.01). No baseline clinical characteristics were associated with a history of immunosuppression. With a median follow up of 59 months, and after adjustment for International Prognostic Index, there was no association of Epstein-Barr Virus positivity or immunosuppression with event-free survival at 24 months (Odds Ratio=0.49; 95% Confidence Interval 0.13-1.84 and Odds Ratio=0.81; 95% Confidence Interval 0.37-1.77) or overall survival (Hazard Ratio=0.86; 95% Confidence Interval 0.38-1.97 and Hazard Ratio=1.00; 95% CI 0.57-1.74). In contrast to non-Western populations, our North American population had a low prevalence of Epstein-Barr Virus positive diffuse large B-cell lymphoma that did not convey an adverse prognosis. A history of immunosuppression, while known to be a risk factor for the development of diffuse large B-cell lymphoma, did not impact subsequent prognosis.
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2018.
All research outputs
#8,085,530
of 27,829,204 outputs
Outputs from Haematologica
#1,962
of 4,894 outputs
Outputs of similar age
#134,415
of 454,038 outputs
Outputs of similar age from Haematologica
#33
of 88 outputs
Altmetric has tracked 27,829,204 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 4,894 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,038 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
